Tirzepatide vs semaglutide: the cost-per-result analysis
Cheaper per month and better value are different questions. Here's the price table and the math that separates them.
The efficacy context, briefly and carefully
In SURMOUNT-1, tirzepatide produced mean weight reductions up to roughly 21% of body weight at 72 weeks at the 15 mg dose. Semaglutide 2.4 mg (Wegovy) produced roughly 15% at 68 weeks in STEP 1. The first true head-to-head in obesity, SURMOUNT-5, reported tirzepatide at about 20% versus semaglutide at about 14% at 72 weeks. In type 2 diabetes, SURPASS-2 showed tirzepatide beating semaglutide 1 mg on both A1C and weight. Averages are not individuals — plenty of patients do exceptionally well on semaglutide, tolerability differs person to person, and drug choice belongs to you and your prescriber. But when comparing prices, it's fair to note the products are not interchangeable on expected results.
What each costs in July 2026
| Option | Typical monthly cash price | Notes |
|---|---|---|
| Brand Zepbound (tirzepatide), retail | ~$1,000–$1,350 | FDA-approved; insurance/PA can change this entirely |
| LillyDirect Zepbound vials | ~$349–$499 (lower doses) | FDA-approved brand, self-pay vial program |
| Brand Wegovy (semaglutide), retail | ~$1,350 list; manufacturer cash options have run near $499 | FDA-approved; verify current NovoCare terms |
| Compounded tirzepatide (flat-rate) | $125–$215 | Not FDA-approved; NexLife $186 flat incl. support |
| Compounded tirzepatide (dose-tiered) | ~$279 intro → $399–$499 | Not FDA-approved; price climbs with dose |
| Compounded semaglutide | ~$99–$299 typical market range | Not FDA-approved; usually the cheapest GLP-1 option |
Advertised/cash figures checked July 2026 and rounded; brand pricing and manufacturer programs change frequently — verify with Lilly, Novo Nordisk, and individual providers.
Cost per point of expected weight loss
Here's the calculation the sticker hides. Take a rough annual cost and divide it by the average trial weight-loss percentage for each product class: compounded semaglutide at ~$200/month is ~$2,400/year against ~14% average loss, or about $170 per point. Compounded tirzepatide at $186/month flat is ~$2,232 against ~20%, or about $112 per point. LillyDirect vials at ~$425 midpoint run about $254 per point; brand retail at ~$1,175 runs about $705. This is deliberately crude — your response, your dose, and your tolerability are not averages — but it shows why "semaglutide is cheaper" and "tirzepatide is the better deal" can both be true at once.
When semaglutide is still the right money answer
Three scenarios flip the math. If your insurance covers Wegovy or Ozempic but not Zepbound, covered semaglutide beats cash-pay anything. If your budget ceiling is around $100–$150/month, compounded semaglutide is the only option that fits, and a medication you can afford consistently beats a stronger one you'll have to quit. And if you tolerate semaglutide well at a response that satisfies you and your clinician, switching for averages makes no sense — trial means describe populations, not you.
Tolerability changes the money math too
Both molecules are titrated slowly for the same reason: gastrointestinal side effects — nausea, diarrhea, constipation — cluster around dose escalations. Where this touches cost: a rougher titration means more provider touchpoints, and on unbundled programs each of those is a billed visit. It can also mean holding at an intermediate dose longer, which on dose-tiered pricing at least stops the price clock, or an occasional restart, which on tiered plans restarts the escalation you already paid through once. Patients with a history of poor GLP-1 tolerance should weight bundled-visit plans more heavily regardless of molecule, because the plan that includes unlimited dose-adjustment consults is the plan whose price doesn't punish a difficult titration.
The switching-cost trap nobody prices
Patients who start on the cheaper molecule intending to "upgrade later" should price the whole journey. Switching usually means a new consultation, sometimes new labs, a fresh titration schedule from a low dose, and — on dose-tiered pricing — restarting the escalation clock. Six months of compounded semaglutide at $200 followed by six months of tiered tirzepatide climbing from $279 to $499 totals around $3,500, more than a full year of flat-rate tirzepatide at $2,232. If tirzepatide is where you and your prescriber expect to end up, starting there on a flat plan is frequently the cheaper path. Our science journal comparison covers the mechanism differences behind the outcome gap.
Quick answers
Is tirzepatide or semaglutide cheaper in 2026?
Per month, compounded semaglutide is usually cheaper (~$99–$299) than compounded tirzepatide ($125–$499 depending on model). Per unit of average trial weight loss, flat-rate compounded tirzepatide often works out cheaper (~$112 vs ~$170 per percentage point per year in our rough model). Brand pricing depends heavily on insurance.
Does tirzepatide work better than semaglutide?
In the SURMOUNT-5 head-to-head trial, tirzepatide produced about 20% average weight loss versus about 14% for semaglutide at 72 weeks. Individual responses vary widely, and which medication is appropriate is a decision for you and a licensed prescriber.
Should I start on semaglutide because it's cheaper and switch later?
Price the whole journey first: switching adds consultations, sometimes labs, and a fresh titration that can restart dose-tiered pricing escalation. Six months of each can cost more than a full year of flat-rate tirzepatide.